California State Teachers Retirement System Acquires 41,734 Shares of Hims & Hers Health, Inc. $HIMS

California State Teachers Retirement System boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 22.4% in the first quarter, Holdings Channel.com reports. The firm owned 228,252 shares of the company’s stock after purchasing an additional 41,734 shares during the quarter. California State Teachers Retirement System’s holdings in Hims & Hers Health were worth $4,739,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in HIMS. Vanguard Group Inc. increased its holdings in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich acquired a new position in Hims & Hers Health during the 4th quarter valued at about $11,187,000. Cunning Capital Partners LP bought a new stake in Hims & Hers Health during the 4th quarter worth approximately $1,110,000. Virtu Financial LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $1,937,000. Finally, Louisiana State Employees Retirement System purchased a new position in shares of Hims & Hers Health during the first quarter valued at approximately $1,254,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $31.58 on Friday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $65.30. The stock has a market capitalization of $7.31 billion, a price-to-earnings ratio of -350.89, a price-to-earnings-growth ratio of 83.47 and a beta of 2.40. The company has a fifty day moving average of $31.86 and a 200-day moving average of $26.10. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 EPS. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Insider Activity

In related news, insider Irene Becklund sold 4,490 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $141,435.00. Following the sale, the insider owned 6,790 shares in the company, valued at $213,885. This represents a 39.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 7,163 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87. Following the completion of the transaction, the chief financial officer owned 284,321 shares in the company, valued at approximately $10,374,873.29. This represents a 2.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HIMS. JPMorgan Chase & Co. dropped their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Weiss Ratings lowered shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $31.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.